Announcement of transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entities



H. Lundbeck A/S hereby reports transactions made by executives and
persons and legal entities closely associated to them with shares in
H. Lundbeck A/S and linked securities, cf. section 28a of the Danish
Securities Trading Act.

The list is based on reports received by H. Lundbeck A/S from the
company's executives today or yesterday.


+-------------------------------------------------------------------+
| Name:                                  | Stig Løkke Pedersen      |
|                                        |                          |
|----------------------------------------+--------------------------|
| Job position of the executive:         | Executive Vice President |
|                                        |                          |
|----------------------------------------+--------------------------|
| Relation to executive (associated      |                          |
| person or legal entity):               |                          |
|----------------------------------------+--------------------------|
| ID code (ISIN code):                   | DK 0010287234            |
|                                        |                          |
|----------------------------------------+--------------------------|
| Description of the security:           | Share                    |
|                                        |                          |
|----------------------------------------+--------------------------|
| Nature of the transaction:             | Sale of shares           |
|                                        |                          |
|----------------------------------------+--------------------------|
| Date of trading:                       | 9 November 2009          |
|                                        |                          |
|----------------------------------------+--------------------------|
| Market on which the trading was        | Nasdaq OMX Copenhagen    |
| effected:                              |                          |
|----------------------------------------+--------------------------|
| Number of traded securities:           |        12,472 | Shares   |
|                                        |               |          |
|----------------------------------------+---------------+----------|
| Market price of securities traded:     |     1,197,312 | DKK      |
|                                        |               |          |
+-------------------------------------------------------------------+




Persons/entities under an obligation to report
Persons or entities under an obligation to report are defined as
members of the Executive Management and the Supervisory Board of H.
Lundbeck A/S and persons/entities closely associated to them.

Closely associated persons/entities means inter alia:
*                      spouse or cohabitant
*                      children below the age of 18
*                      legal entities in which the insider has a
  controlling influence

The content of this release will have no influence on the Lundbeck
Group's financial result for 2009.


Lundbeck contacts


Investors:                   Media:

Jacob Tolstrup               Mads Kronborg
Director, IR & Communication Media Relations
+45 36 43 30 79              +45 36 43 28 51

Palle Holm Olesen            Kasper Riis
Head of Investor Relations   Media Relations
+45 36 43 24 26              +45 36 43 28 33

Magnus Thorstholm Jensen
Investor Relations Officer
+45 36 43 38 16



About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international
pharmaceutical company highly committed to improve the quality of
life for people suffering from central nervous system (CNS)
disorders. For this purpose Lundbeck is engaged in the research and
development, production, marketing and sale of pharmaceuticals across
the world, targeted at disorders like depression and anxiety,
schizophrenia, insomnia, Huntington's, Alzheimer's and Parkinson's
diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark,
and employs today over 5,500 people worldwide. Lundbeck is one of the
world's leading pharmaceutical companies working with CNS disorders.
In 2008, the company's revenue was DKK 11.3 billion (approximately
EUR 1.5 billion or USD 2.2 billion). For more information, please
visit www.lundbeck.com.

Attachments

Release no 389.pdf